# Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Canonical URL: https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates
Ticker: BEAM
Company: Beam Therapeutics
Source: Beam Therapeutics
Published: 2026-05-07 11:00 EST
Original Source URL: https://investors.beamtx.com
## Summary

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel

## Article Body
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel
## Recent Company News
- 2026-05-18 20:00 EST — [Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-presents-recently-reported-topline-clinical-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-american-thoracic-society-ats-2026-international-conference) — Source: Beam Therapeutics
- 2026-05-13 11:00 EST — [Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-2026-rbc-capital-markets-global-healthcare-conference) — Source: Beam Therapeutics
- 2026-05-12 13:30 EST — [Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell-health-and-function-in-sickle-cell-disease-at-eha2026) — Source: Beam Therapeutics
- 2026-05-07 11:00 EST — [Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates) — Source: Beam Therapeutics
- 2026-04-01 21:12 EST — [Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine](https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine) — Source: Beam Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)